含有hesperidin的纳米粒子通过调节视网膜免疫微环境来减轻氧气诱导视网膜病变中的病态血管生成
Minglan Wang1,2, Menglei Wang1,2, Changhao Dong2
1The Second Clinical College, Chongqing Medical University, Chongqing 400010, China.
ACS biomaterials science & engineering
|February 25, 2026
概括
一种新的纳米粒子疗法针对M1微质,将其重新编程为抗炎M2表型. 这种方法减少了视网膜炎症和病态血管生成,为新血管化提供了有前途的治疗方法.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 纳米技术 纳米技术
背景情况:
- 视网膜新血管化是由炎症驱动的,微质细胞发挥着关键作用.
- 高流动性组盒子1 (HMGB1) 促进促炎M1微质,加剧视网膜损伤.
- 将微质从M1转移到抗炎M2表型是一种潜在的治疗策略.
研究的目的:
- 开发一种有针对性的疗法来调节微质M1/M2极化.
- 抑制病态血管生成和视网膜炎症.
- 为网膜新血管化提供一种新的治疗方法.
主要方法:
- 设计了一个纳米粒子 (H-H@MG1),封装hesperidin,并针对M1微质细胞.
- 进行了体外研究,以评估纳米粒子对微质偏极化的疗效.
- 使用氧气诱导视网膜病变的小鼠模型进行体内验证.
主要成果:
- 在实验室中,H-H@MG1纳米粒子选择性地向M1微质,抑制HMGB1激活并促进M2极化.
- 在体内研究表明,H-H@MG1在视网膜中重新平衡了M1/M2极化.
- 减少了促炎性细胞因子 (IL-6,TNF-α) 和抑制了病理性血管生成.
结论:
- H-H@MG1纳米输送系统有效地重塑了视网膜免疫微环境.
- 这一策略在通过减少炎症和血管生成来治疗视网膜新血管化的治疗方面表现有前途.
- 准微质偏向为神经血管眼病提供了可行的治疗途径.
相关概念视频
01:24Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
01:10Mechanism of Angiogenesis
7.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K